P696 The usefulness to treatment enhancement for the patients of ulcerative colitis with clinical remission diagnosed as Mayo endoscopic subscore 1
ECCO'20 Vienna
2020
P697 Efficacy and safety of ustekinumab in Crohn’s disease: A real-world study from Australia
ECCO'20 Vienna
2020
P699 The concordance of Short Form-36 Health Survey scores with Mayo scores in the tofacitinib ulcerative colitis clinical programme
ECCO'20 Vienna
2020
P700 Effect of vitamin D in disease activity score and clinical relapse in patients with inflammatory bowel disease: A systematic review and meta-analysis
ECCO'20 Vienna
2020
P702 Treatment decisions in older inflammatory bowel disease patients: Applying gut feeling in an evidence-based era? A qualitative study
ECCO'20 Vienna
2020
P704 The biennial direct pharmaceutical costs per treatment with biologics for the inflammatory bowel disease in Greece: A comparative calculation study
ECCO'20 Vienna
2020
P705 Dietary practices and beliefs of patients with older-onset inflammatory bowel disease: A prospective UK study
ECCO'20 Vienna
2020
P706 Adalimumab drug levels at secondary loss of response in Crohn’s disease; are we aiming high enough? A retrospective, international multi-centre study
ECCO'20 Vienna
2020
P707 Anti-TNFα therapy has no effect on bone mineral density in younger patients with inflammatory bowel disease: A single-centre observational study
ECCO'20 Vienna
2020
P708 The effect of psychotherapy on quality of life in inflammatory bowel disease patients: A systematic literature review
ECCO'20 Vienna
2020
P709 Is azathioprine safe as long-term treatment in paediatric patients with inflammatory bowel disease?
ECCO'20 Vienna
2020
P710 The influence of probiotics to the efficacy of 5-ASA for the patients of ulcerative colitis
ECCO'20 Vienna
2020
P711 Carriage of the HLA-DQA1*05 allele is associated with a high risk of loss of response to adalimumab in patients with Crohn’s disease
ECCO'20 Vienna
2020